https://www.321223.comnone 2026-11-10 03:39:18 daily 0.8 https://www.321223.com/xwdt/xydt/ 2026-11-10 03:38:58 daily 0.8 https://www.321223.com/xwdt/xjz/ 2026-11-10 03:38:38 daily 0.8 https://www.321223.com/xwdt/html/990.html 2026-11-10 03:38:18 daily 0.8 https://www.321223.com/xwdt/html/979.html 2026-11-10 03:37:58 daily 0.8 https://www.321223.com/xwdt/html/967.html 2026-11-10 03:37:38 daily 0.8 https://www.321223.com/xwdt/html/943.html 2026-11-10 03:37:18 daily 0.8 https://www.321223.com/xwdt/html/927.html 2026-11-10 03:36:58 daily 0.8 https://www.321223.com/xwdt/html/907.html 2026-11-10 03:36:38 daily 0.8 https://www.321223.com/xwdt/html/900.html 2026-11-10 03:36:18 daily 0.8 https://www.321223.com/xwdt/html/897.html 2026-11-10 03:35:58 daily 0.8 https://www.321223.com/xwdt/html/729.html 2026-11-10 03:35:38 daily 0.8 https://www.321223.com/xwdt/html/656.html 2026-11-10 03:35:18 daily 0.8 https://www.321223.com/xwdt/html/592.html 2026-11-10 03:34:58 daily 0.8 https://www.321223.com/xwdt/html/575.html 2026-11-10 03:34:38 daily 0.8 https://www.321223.com/xwdt/html/557.html 2026-11-10 03:34:18 daily 0.8 https://www.321223.com/xwdt/html/488.html 2026-11-10 03:33:58 daily 0.8 https://www.321223.com/xwdt/html/465.html 2026-11-10 03:33:38 daily 0.8 https://www.321223.com/xwdt/html/419.html 2026-11-10 03:33:18 daily 0.8 https://www.321223.com/xwdt/html/348.html 2026-11-10 03:32:58 daily 0.8 https://www.321223.com/xwdt/html/314.html 2026-11-10 03:32:38 daily 0.8 https://www.321223.com/xwdt/html/270.html 2026-11-10 03:32:18 daily 0.8 https://www.321223.com/xwdt/html/233.html 2026-11-10 03:31:58 daily 0.8 https://www.321223.com/xwdt/html/1310.html 2026-11-10 03:31:38 daily 0.8 https://www.321223.com/xwdt/html/1304.html 2026-11-10 03:31:18 daily 0.8 https://www.321223.com/xwdt/html/1303.html 2026-11-10 03:30:58 daily 0.8 https://www.321223.com/xwdt/html/1302.html 2026-11-10 03:30:38 daily 0.8 https://www.321223.com/xwdt/html/1301.html 2026-11-10 03:30:18 daily 0.8 https://www.321223.com/xwdt/html/1300.html 2026-11-10 03:29:58 daily 0.8 https://www.321223.com/xwdt/html/1297.html 2026-11-10 03:29:38 daily 0.8 https://www.321223.com/xwdt/html/1296.html 2026-11-10 03:29:18 daily 0.8 https://www.321223.com/xwdt/html/1295.html 2026-11-10 03:28:58 daily 0.8 https://www.321223.com/xwdt/html/1294.html 2026-11-10 03:28:38 daily 0.8 https://www.321223.com/xwdt/html/1286.html 2026-11-10 03:28:18 daily 0.8 https://www.321223.com/xwdt/html/1275.html 2026-11-10 03:27:58 daily 0.8 https://www.321223.com/xwdt/html/1274.html 2026-11-10 03:27:38 daily 0.8 https://www.321223.com/xwdt/html/1273.html 2026-11-10 03:27:18 daily 0.8 https://www.321223.com/xwdt/html/1272.html 2026-11-10 03:26:58 daily 0.8 https://www.321223.com/xwdt/html/1271.html 2026-11-10 03:26:38 daily 0.8 https://www.321223.com/xwdt/html/1270.html 2026-11-10 03:26:18 daily 0.8 https://www.321223.com/xwdt/html/1259.html 2026-11-10 03:25:58 daily 0.8 https://www.321223.com/xwdt/html/1258.html 2026-11-10 03:25:38 daily 0.8 https://www.321223.com/xwdt/html/1257.html 2026-11-10 03:25:18 daily 0.8 https://www.321223.com/xwdt/html/1256.html 2026-11-10 03:24:58 daily 0.8 https://www.321223.com/xwdt/html/1255.html 2026-11-10 03:24:38 daily 0.8 https://www.321223.com/xwdt/html/1254.html 2026-11-10 03:24:18 daily 0.8 https://www.321223.com/xwdt/html/1253.html 2026-11-10 03:23:58 daily 0.8 https://www.321223.com/xwdt/html/1251.html 2026-11-10 03:23:38 daily 0.8 https://www.321223.com/xwdt/html/1250.html 2026-11-10 03:23:18 daily 0.8 https://www.321223.com/xwdt/html/1249.html 2026-11-10 03:22:58 daily 0.8 https://www.321223.com/xwdt/html/1248.html 2026-11-10 03:22:38 daily 0.8 https://www.321223.com/xwdt/html/1247.html 2026-11-10 03:22:18 daily 0.8 https://www.321223.com/xwdt/html/1246.html 2026-11-10 03:21:58 daily 0.8 https://www.321223.com/xwdt/html/1245.html 2026-11-10 03:21:38 daily 0.8 https://www.321223.com/xwdt/html/1241.html 2026-11-10 03:21:18 daily 0.8 https://www.321223.com/xwdt/html/1240.html 2026-11-10 03:20:58 daily 0.8 https://www.321223.com/xwdt/html/1235.html 2026-11-10 03:20:38 daily 0.8 https://www.321223.com/xwdt/html/1234.html 2026-11-10 03:20:18 daily 0.8 https://www.321223.com/xwdt/html/1226.html 2026-11-10 03:19:58 daily 0.8 https://www.321223.com/xwdt/html/1225.html 2026-11-10 03:19:38 daily 0.8 https://www.321223.com/xwdt/html/1224.html 2026-11-10 03:19:18 daily 0.8 https://www.321223.com/xwdt/html/1200.html 2026-11-10 03:18:58 daily 0.8 https://www.321223.com/xwdt/html/1199.html 2026-11-10 03:18:38 daily 0.8 https://www.321223.com/xwdt/gsxw/ 2026-11-10 03:18:18 daily 0.8 https://www.321223.com/media/zyupr30a/hkex-eps_20260930_12354321_0.pdf 2026-11-10 03:17:58 daily 0.8 https://www.321223.com/media/znwhl4oq/final-2025-esmo-ct041-poster.pdf 2026-11-10 03:17:38 daily 0.8 https://www.321223.com/media/xvghsvht/2022-interim-report.pdf 2026-11-10 03:17:18 daily 0.8 https://www.321223.com/media/xmlelc50/poster_abstract-2557.pdf 2026-11-10 03:16:58 daily 0.8 https://www.321223.com/media/wsnbvqta/通用型car-t产品ct0596及ct1190b的积极临床数据.pdf 2026-11-10 03:16:38 daily 0.8 https://www.321223.com/media/wsnbvqta/ͨ����car-t��Ʒct0596��ct1190b�Ļ����ٴ�����.pdf 2026-11-10 03:16:18 daily 0.8 https://www.321223.com/media/wncfkrfb/公示件-泽沃基奥仑赛注射液使用培训和认证的医疗机构名单汇总-0720.pdf 2026-11-10 03:15:58 daily 0.8 https://www.321223.com/media/wivjdipc/2023-hy.pdf 2026-11-10 03:15:38 daily 0.8 https://www.321223.com/media/wccjzwma/positive-clinical-data-for-allogeneic-car-t-products-ct0596-and-ct1190b.pdf 2026-11-10 03:15:18 daily 0.8 https://www.321223.com/media/vujmc2eu/green-application-form.pdf 2026-11-10 03:14:58 daily 0.8 https://www.321223.com/media/vtudbnl4/final-2025-asco-oral-presentation.pdf 2026-11-10 03:14:38 daily 0.8 https://www.321223.com/media/vtoc44bj/en_hkex-eps_20240909_11360644_0.pdf 2026-11-10 03:14:18 daily 0.8 https://www.321223.com/media/vbnbibn2/general_terms_and_conditions_of_purchase_carsgen_us_final_20231110.pdf 2026-11-10 03:13:58 daily 0.8 https://www.321223.com/media/ub5lsa0p/car-tcr-summit-2022-final.pdf 2026-11-10 03:13:38 daily 0.8 https://www.321223.com/media/u1wdz4jn/hkex-eps_20241210_11472656_0.pdf 2026-11-10 03:13:18 daily 0.8 https://www.321223.com/media/tz2paqen/global-offering-2-cn.pdf 2026-11-10 03:12:58 daily 0.8 https://www.321223.com/media/txzffkap/hkex-eps_20221209_10538157_0fan.pdf 2026-11-10 03:12:38 daily 0.8 https://www.321223.com/media/tu3jixci/hkex-eps_20230419_10692749_0_en.pdf 2026-11-10 03:12:18 daily 0.8 https://www.321223.com/media/t5zguoik/hkex-eps_20260930_12354322_0.pdf 2026-11-10 03:11:58 daily 0.8 https://www.321223.com/media/t5knxqvb/1751.pdf 2026-11-10 03:11:38 daily 0.8 https://www.321223.com/media/syrk40jm/final-carsgen-therapeutics-corporate-deck_oct-28.pdf 2026-11-10 03:11:18 daily 0.8 https://www.321223.com/media/suzbnpln/eha-2025-ct071-pf1164_juan-du.pdf 2026-11-10 03:10:58 daily 0.8 https://www.321223.com/media/stwjmue4/final-�Ƽ�ҩҵ��˾����-oct-13.pdf 2026-11-10 03:10:38 daily 0.8 https://www.321223.com/media/stwjmue4/final-Z6尊龙凯时药业公司介绍-oct-13.pdf 2026-11-10 03:10:18 daily 0.8 https://www.321223.com/media/rzmju0v4/ct0596-eha2026-poster-final-1.pdf 2026-11-10 03:09:58 daily 0.8 https://www.321223.com/media/rqfnslii/2024041800870_c.pdf 2026-11-10 03:09:38 daily 0.8 https://www.321223.com/media/pudgixhi/aacr-cldn18-2-poster.pdf 2026-11-10 03:08:58 daily 0.8 https://www.321223.com/media/pp2bzlw0/�Ƽ�ҩҵ2025Ͷ���߿�����.pdf 2026-11-10 03:08:38 daily 0.8 https://www.321223.com/media/pp2bzlw0/Z6尊龙凯时药业2025投资者盛开日.pdf 2026-11-10 03:08:18 daily 0.8 https://www.321223.com/media/pmglacuc/2023-hy-e.pdf 2026-11-10 03:07:58 daily 0.8 https://www.321223.com/media/pjrcksuy/global-offering.pdf 2026-11-10 03:07:38 daily 0.8 https://www.321223.com/media/oy2arfcg/poster-1056p.pdf 2026-11-10 03:07:18 daily 0.8 https://www.321223.com/media/otzepuxu/contractual-arrangements-which-are-material-contracts.pdf 2026-11-10 03:06:58 daily 0.8 https://www.321223.com/media/o3nbxckn/2022-ash.pdf 2026-11-10 03:06:38 daily 0.8 https://www.321223.com/media/o2hhwg5j/procedures-for-shareholders-to-propose-directors-en.pdf 2026-11-10 03:06:18 daily 0.8 https://www.321223.com/media/nfkjdysh/e_ham25051660ann-20250904-20250904_1323.pdf 2026-11-10 03:05:58 daily 0.8 https://www.321223.com/media/n2ih2b4l/carsgen-therapeutics-2025-investor-day.pdf 2026-11-10 03:05:38 daily 0.8 https://www.321223.com/media/mi3ppjp2/final-�Ƽ�ҩҵ��˾����-oct-28.pdf 2026-11-10 03:05:18 daily 0.8 https://www.321223.com/media/mi3ppjp2/final-Z6尊龙凯时药业公司介绍-oct-28.pdf 2026-11-10 03:04:38 daily 0.8 https://www.321223.com/media/mckjltow/2025-interim-report.pdf 2026-11-10 03:04:18 daily 0.8 https://www.321223.com/media/mbijtrcb/final-�Ƽ�ҩҵ��˾����-sept-1.pdf 2026-11-10 03:03:58 daily 0.8 https://www.321223.com/media/mbijtrcb/final-Z6尊龙凯时药业公司介绍-sept-1.pdf 2026-11-10 03:03:38 daily 0.8 https://www.321223.com/media/malcgk31/green-application-form-cn.pdf 2026-11-10 03:03:18 daily 0.8 https://www.321223.com/media/lzxm1ezb/4845_ash-poster.pdf 2026-11-10 03:02:38 daily 0.8 https://www.321223.com/media/lwmjqyw3/2821.pdf 2026-11-10 03:02:18 daily 0.8 https://www.321223.com/media/llznor0x/2023-asco-gi-poster_ab011-mono-combo-_0106final.pdf 2026-11-10 03:01:38 daily 0.8 https://www.321223.com/media/lgei54pn/global-offering-2.pdf 2026-11-10 03:01:18 daily 0.8 https://www.321223.com/media/kv3nfwei/2021-annual-report-en.pdf 2026-11-10 03:00:58 daily 0.8 https://www.321223.com/media/kuxd30iu/final-carsgen-therapeutics-corporate-deck_sept-1.pdf 2026-11-10 03:00:38 daily 0.8 https://www.321223.com/media/kolhjqpf/2022-interim-report-cn.pdf 2026-11-10 03:00:18 daily 0.8 https://www.321223.com/media/jyyh33c4/2021-esmo-ct041-oral-presentation.pdf 2026-11-10 02:59:58 daily 0.8 https://www.321223.com/media/jyvpmslq/hkex-eps_20260915_12332734_0.pdf 2026-11-10 02:59:38 daily 0.8 https://www.321223.com/media/iznib0sv/c_ham25051660ann-20250904-20250904_1325.pdf 2026-11-10 02:59:18 daily 0.8 https://www.321223.com/media/i4bdwekv/carsgen_arrangements-of-electronic-dissemination-of-corporate-communications_en.pdf 2026-11-10 02:58:58 daily 0.8 https://www.321223.com/media/hn1pbu44/2022_asco_annual_meeting_poster_14may2022.pdf 2026-11-10 02:58:38 daily 0.8 https://www.321223.com/media/hiuks2qn/ct041-cg4006-asco-2024_v3-0_20240603-1.pdf 2026-11-10 02:58:18 daily 0.8 https://www.321223.com/media/hgpk5qic/hkex-eps_20241210_11472655_0.pdf 2026-11-10 02:57:58 daily 0.8 https://www.321223.com/media/ghcj2aj4/cn_hkex-eps_20240909_11360645_0.pdf 2026-11-10 02:57:38 daily 0.8 https://www.321223.com/media/gdon4wmr/ct0596-ash-poster-20251110-for-submision.pdf 2026-11-10 02:57:18 daily 0.8 https://www.321223.com/media/g4aoe02d/公示文件-舒瑞基奥仑赛注射液使用培训和认证的医疗机构名单-0720.pdf 2026-11-10 02:56:58 daily 0.8 https://www.321223.com/media/fdyfi4ug/carsgen_arrangements-of-electronic-dissemination-of-corporate-communications_cn.pdf 2026-11-10 02:56:38 daily 0.8 https://www.321223.com/media/f5pblhde/ct053-ash-poster_-4762.pdf 2026-11-10 02:56:18 daily 0.8 https://www.321223.com/media/f1jny5l1/sitc-2023-poster.pdf 2026-11-10 02:55:38 daily 0.8 https://www.321223.com/media/eb0lckhd/2021-esmo-ct041-口头汇报.pdf 2026-11-10 02:55:18 daily 0.8 https://www.321223.com/media/eatjktro/hkex-eps_20260410_12102280_0.pdf 2026-11-10 02:54:58 daily 0.8 https://www.321223.com/media/dxnj3spj/ct0590-ash-poster_-4843.pdf 2026-11-10 02:54:38 daily 0.8 https://www.321223.com/media/djkf4urr/hkex-eps_20221209_10538156_0en.pdf 2026-11-10 02:54:18 daily 0.8 https://www.321223.com/media/caaamxan/hkex-eps_20260522_12169562_0.pdf 2026-11-10 02:53:58 daily 0.8 https://www.321223.com/media/brtijrlk/2021-annual-report.pdf 2026-11-10 02:53:38 daily 0.8 https://www.321223.com/media/brqhxcy4/2024041800869.pdf 2026-11-10 02:53:18 daily 0.8 https://www.321223.com/media/agmjug4b/final-eha2024-ppt-v2_clean_06.pdf 2026-11-10 02:52:58 daily 0.8 https://www.321223.com/media/5yod15ea/abstract-4095_ct0180_poster.pdf 2026-11-10 02:52:18 daily 0.8 https://www.321223.com/media/5owm5t4b/global-offering-cn.pdf 2026-11-10 02:51:58 daily 0.8 https://www.321223.com/media/5drbms3p/2024-annual-report-c.pdf 2026-11-10 02:51:38 daily 0.8 https://www.321223.com/media/4tejef2g/2025-interim-report-c.pdf 2026-11-10 02:51:18 daily 0.8 https://www.321223.com/media/4hyptsvx/ct1190b-ps2064_ye-1.pdf 2026-11-10 02:50:58 daily 0.8 https://www.321223.com/media/4cbfepok/hkex-eps_20260915_12332733_0.pdf 2026-11-10 02:50:38 daily 0.8 https://www.321223.com/media/3vsj00ph/2024-annual-report.pdf 2026-11-10 02:50:18 daily 0.8 https://www.321223.com/media/3bzk0o35/hkex-eps_20260522_12169561_0.pdf 2026-11-10 02:49:58 daily 0.8 https://www.321223.com/media/3byc3vpp/hkex-eps_20230419_10692750_0_hk.pdf 2026-11-10 02:49:38 daily 0.8 https://www.321223.com/media/2w4bh31e/procedures-for-shareholders-to-propose-directors-cn.pdf 2026-11-10 02:49:18 daily 0.8 https://www.321223.com/media/2rwlk1zn/final-carsgen-therapeutics-corporate-deck_oct-13.pdf 2026-11-10 02:48:58 daily 0.8 https://www.321223.com/media/2kygbdc3/final-p941_du.pdf 2026-11-10 02:48:38 daily 0.8 https://www.321223.com/media/1w1dumr5/final-ims_poster_pa-029_id-number-3173032-v2-1.pdf 2026-11-10 02:48:18 daily 0.8 https://www.321223.com/media/1s3dnn3g/blue-asco-poster-gpb-05-19-2023-final.pdf 2026-11-10 02:47:38 daily 0.8 https://www.321223.com/media/1rjd2yul/hkex-eps_20260410_12102281_0.pdf 2026-11-10 02:47:18 daily 0.8 https://www.321223.com/media/1gwa3sdq/ct041-st-02-phase-1b-cohort-a-2024-asco-gi-poster_final.pdf 2026-11-10 02:46:58 daily 0.8 https://www.321223.com/media/0yylooxm/ct071-ash-poster_-3451.pdf 2026-11-10 02:46:38 daily 0.8 https://www.321223.com/media/0klf3v3t/ct041-st-01-abs4017-poster_final.pdf 2026-11-10 02:46:18 daily 0.8 https://www.321223.com/lxwm/ 2026-11-10 02:45:58 daily 0.8 https://www.321223.com/jrwm/ 2026-11-10 02:45:38 daily 0.8 https://www.321223.com/jjfa/ 2026-11-10 02:45:18 daily 0.8 https://www.321223.com/html/web/xinwenzhongxin/shipinzhuanqu/index.html 2026-11-10 02:44:58 daily 0.8 https://www.321223.com/html/web/xinwenzhongxin/fangdaxinwen/index.html 2026-11-10 02:44:38 daily 0.8 https://www.321223.com/html/web/touziyuhezuo/zhaobiaogonggao/index.html 2026-11-10 02:44:18 daily 0.8 https://www.321223.com/html/web/touziyuhezuo/shangshigongsi/index.html 2026-11-10 02:43:58 daily 0.8 https://www.321223.com/html/web/shehuizeren/zhichiguofang/index.html 2026-11-10 02:43:38 daily 0.8 https://www.321223.com/html/web/shehuizeren/yifanashui/index.html 2026-11-10 02:43:18 daily 0.8 https://www.321223.com/html/web/shehuizeren/shehuigongyi/index.html 2026-11-10 02:42:58 daily 0.8 https://www.321223.com/html/web/shehuizeren/jienenghuanbao/index.html 2026-11-10 02:42:38 daily 0.8 https://www.321223.com/html/web/shehuizeren/baozhangjiuye/index.html 2026-11-10 02:42:18 daily 0.8 https://www.321223.com/html/web/rencaifazhan/zhaopingonggao/index.html 2026-11-10 02:41:58 daily 0.8 https://www.321223.com/html/web/guanyuwomen/zuzhijiagou/index.html 2026-11-10 02:41:38 daily 0.8 https://www.321223.com/html/web/guanyuwomen/fazhanlicheng/index.html 2026-11-10 02:41:18 daily 0.8 https://www.321223.com/html/web/guanyuwomen/fangdarongyu/index.html 2026-11-10 02:40:58 daily 0.8 https://www.321223.com/html/web/guanyuwomen/fangdajianjie/index.html 2026-11-10 02:40:38 daily 0.8 https://www.321223.com/html/web/dangjianwenhua/xingfufangda/index.html 2026-11-10 02:40:18 daily 0.8 https://www.321223.com/html/web/dangjianwenhua/qiyelinian/index.html 2026-11-10 02:39:58 daily 0.8 https://www.321223.com/html/web/dangjianwenhua/dangqunhuodong/index.html 2026-11-10 02:39:38 daily 0.8 https://www.321223.com/html/web/chengyuandanwei/yiyao/index.html 2026-11-10 02:39:18 daily 0.8 https://www.321223.com/html/web/chengyuandanwei/tansu/index.html 2026-11-10 02:38:58 daily 0.8 https://www.321223.com/html/web/chengyuandanwei/shangye/index.html 2026-11-10 02:38:38 daily 0.8 https://www.321223.com/html/web/chengyuandanwei/hangkong/index.html 2026-11-10 02:38:18 daily 0.8 https://www.321223.com/html/web/chengyuandanwei/gangtie/index.html 2026-11-10 02:37:58 daily 0.8 https://www.321223.com/hk/privacy-policy/ 2026-11-10 02:37:38 daily 0.8 https://www.321223.com/hk/pipeline/ 2026-11-10 02:37:18 daily 0.8 https://www.321223.com/hk/our-approach/technologies/ 2026-11-10 02:36:58 daily 0.8 https://www.321223.com/hk/our-approach/publications/?page=1 2026-11-10 02:36:38 daily 0.8 https://www.321223.com/hk/our-approach/publications/ 2026-11-10 02:36:18 daily 0.8 https://www.321223.com/hk/our-approach/manufacturing/ 2026-11-10 02:35:58 daily 0.8 https://www.321223.com/hk/our-approach/ 2026-11-10 02:35:38 daily 0.8 https://www.321223.com/hk/news/�Ƽ�ҩҵct041����asco-�״ι�������ע���ٴ���������/ 2026-11-10 02:35:18 daily 0.8 https://www.321223.com/hk/news/?page=4 2026-11-10 02:34:58 daily 0.8 https://www.321223.com/hk/news/?page=3 2026-11-10 02:34:38 daily 0.8 https://www.321223.com/hk/news/?page=2 2026-11-10 02:34:18 daily 0.8 https://www.321223.com/hk/news/?page=1 2026-11-10 02:33:58 daily 0.8 https://www.321223.com/hk/news/20191209/ 2026-11-10 02:33:38 daily 0.8 https://www.321223.com/hk/news/20190301/ 2026-11-10 02:33:18 daily 0.8 https://www.321223.com/hk/news/20190129/ 2026-11-10 02:32:58 daily 0.8 https://www.321223.com/hk/news/20190128/ 2026-11-10 02:32:38 daily 0.8 https://www.321223.com/hk/news/20170810/ 2026-11-10 02:32:18 daily 0.8 https://www.321223.com/hk/news/ 2026-11-10 02:31:58 daily 0.8 https://www.321223.com/hk/investors/listing-documents/ 2026-11-10 02:31:38 daily 0.8 https://www.321223.com/hk/investors/ir-contact/ 2026-11-10 02:31:18 daily 0.8 https://www.321223.com/hk/investors/financial-reports/ 2026-11-10 02:30:58 daily 0.8 https://www.321223.com/hk/investors/corporate-governance/ 2026-11-10 02:30:38 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=5 2026-11-10 02:30:18 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=4 2026-11-10 02:29:58 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=3 2026-11-10 02:29:38 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=2 2026-11-10 02:29:18 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=1 2026-11-10 02:28:58 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/ 2026-11-10 02:28:38 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/?page=5 2026-11-10 02:28:18 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/?page=4 2026-11-10 02:27:58 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/?page=3 2026-11-10 02:27:38 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/?page=2 2026-11-10 02:27:18 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/?page=1 2026-11-10 02:26:58 daily 0.8 https://www.321223.com/hk/investors/corporate-deck-presentations/ 2026-11-10 02:26:38 daily 0.8 https://www.321223.com/hk/investors/announcements-circulars/ 2026-11-10 02:26:18 daily 0.8 https://www.321223.com/hk/investors/ 2026-11-10 02:25:58 daily 0.8 https://www.321223.com/hk/disclaimer/ 2026-11-10 02:25:38 daily 0.8 https://www.321223.com/hk/contact-us/ 2026-11-10 02:25:18 daily 0.8 https://www.321223.com/hk/careers/join-us/ 2026-11-10 02:24:58 daily 0.8 https://www.321223.com/hk/careers/ 2026-11-10 02:24:38 daily 0.8 https://www.321223.com/hk/about-us/vision-mission-values/ 2026-11-10 02:24:18 daily 0.8 https://www.321223.com/hk/about-us/partnering/ 2026-11-10 02:23:58 daily 0.8 https://www.321223.com/hk/about-us/company-overview/ 2026-11-10 02:23:38 daily 0.8 https://www.321223.com/hk/about-us/ 2026-11-10 02:23:18 daily 0.8 https://www.321223.com/hk/ 2026-11-10 02:22:58 daily 0.8 https://www.321223.com/gydk/ryzz/ 2026-11-10 02:22:38 daily 0.8 https://www.321223.com/gydk/qysl/ 2026-11-10 02:22:18 daily 0.8 https://www.321223.com/gydk/gywm/ 2026-11-10 02:21:58 daily 0.8 https://www.321223.com/en/privacy-policy/ 2026-11-10 02:21:38 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/mab/kj-c2630/ 2026-11-10 02:21:18 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/mab/kj-c2527/ 2026-11-10 02:20:58 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/mab/kj-c2526/ 2026-11-10 02:20:38 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/mab/ct1390b/ 2026-11-10 02:20:18 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/mab/ct1190b-kj-c2219/ 2026-11-10 02:19:58 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/mab/ct0596/ 2026-11-10 02:19:38 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/mab/ 2026-11-10 02:19:18 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/in-vivo-car-t/kj-c2635/ 2026-11-10 02:18:58 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/in-vivo-car-t/kj-c2634/ 2026-11-10 02:18:38 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/in-vivo-car-t/kj-c2633/ 2026-11-10 02:18:18 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/in-vivo-car-t/kj-c2632/ 2026-11-10 02:17:58 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/in-vivo-car-t/kj-c2529/ 2026-11-10 02:17:38 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/in-vivo-car-t/ 2026-11-10 02:17:18 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/car-t-cell-therapies/zevor-cel-ct053-3/ 2026-11-10 02:16:58 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/car-t-cell-therapies/ct041/ 2026-11-10 02:16:38 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/car-t-cell-therapies/ 2026-11-10 02:16:18 daily 0.8 https://www.321223.com/en/pipeline/new-pipeline/ 2026-11-10 02:15:58 daily 0.8 https://www.321223.com/en/pipeline/expanded-access/ 2026-11-10 02:15:38 daily 0.8 https://www.321223.com/en/pipeline/ 2026-11-10 02:15:18 daily 0.8 https://www.321223.com/en/our-approach/technologies/ 2026-11-10 02:14:58 daily 0.8 https://www.321223.com/en/our-approach/publications/zevorcabtagene-autoleucel-first-approval/ 2026-11-10 02:14:38 daily 0.8 https://www.321223.com/en/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-κb-icam1-signaling/ 2026-11-10 02:14:18 daily 0.8 https://www.321223.com/en/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-��b-icam1-signaling/ 2026-11-10 02:13:58 daily 0.8 https://www.321223.com/en/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-%CE%BAb-icam1-signaling/?page=5 2026-11-10 02:13:38 daily 0.8 https://www.321223.com/en/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-%CE%BAb-icam1-signaling/?page=4 2026-11-10 02:13:18 daily 0.8 https://www.321223.com/en/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-%CE%BAb-icam1-signaling/?page=2 2026-11-10 02:12:58 daily 0.8 https://www.321223.com/en/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-%CE%BAb-icam1-signaling/?page=1 2026-11-10 02:12:38 daily 0.8 https://www.321223.com/en/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/?page=4 2026-11-10 02:12:18 daily 0.8 https://www.321223.com/en/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/?page=2 2026-11-10 02:11:58 daily 0.8 https://www.321223.com/en/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/?page=1 2026-11-10 02:11:38 daily 0.8 https://www.321223.com/en/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/ 2026-11-10 02:11:18 daily 0.8 https://www.321223.com/en/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/?page=5 2026-11-10 02:10:58 daily 0.8 https://www.321223.com/en/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/?page=4 2026-11-10 02:10:38 daily 0.8 https://www.321223.com/en/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/?page=2 2026-11-10 02:10:18 daily 0.8 https://www.321223.com/en/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/?page=1 2026-11-10 02:09:58 daily 0.8 https://www.321223.com/en/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/ 2026-11-10 02:09:38 daily 0.8 https://www.321223.com/en/our-approach/publications/combined-local-therapy-and-car-gpc3/?page=5 2026-11-10 02:09:18 daily 0.8 https://www.321223.com/en/our-approach/publications/combined-local-therapy-and-car-gpc3/?page=4 2026-11-10 02:08:58 daily 0.8 https://www.321223.com/en/our-approach/publications/combined-local-therapy-and-car-gpc3/?page=2 2026-11-10 02:08:38 daily 0.8 https://www.321223.com/en/our-approach/publications/combined-local-therapy-and-car-gpc3/?page=1 2026-11-10 02:08:18 daily 0.8 https://www.321223.com/en/our-approach/publications/combined-local-therapy-and-car-gpc3/ 2026-11-10 02:07:58 daily 0.8 https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/?page=5 2026-11-10 02:07:38 daily 0.8 https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/?page=4 2026-11-10 02:07:18 daily 0.8 https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/?page=2 2026-11-10 02:06:58 daily 0.8 https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/?page=1 2026-11-10 02:06:38 daily 0.8 https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/ 2026-11-10 02:06:18 daily 0.8 https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/?page=4 2026-11-10 02:05:58 daily 0.8 https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/?page=2 2026-11-10 02:05:38 daily 0.8 https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/?page=1 2026-11-10 02:05:18 daily 0.8 https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/ 2026-11-10 02:04:58 daily 0.8 https://www.321223.com/en/our-approach/publications/chimeric-anti-gpc3-sfv-cd3ε-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/ 2026-11-10 02:04:38 daily 0.8 https://www.321223.com/en/our-approach/publications/chimeric-anti-gpc3-sfv-cd3��-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/ 2026-11-10 02:04:18 daily 0.8 https://www.321223.com/en/our-approach/publications/chimeric-anti-gpc3-sfv-cd3%CE%B5-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/?page=5 2026-11-10 02:03:58 daily 0.8 https://www.321223.com/en/our-approach/publications/chimeric-anti-gpc3-sfv-cd3%CE%B5-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/?page=4 2026-11-10 02:03:38 daily 0.8 https://www.321223.com/en/our-approach/publications/chimeric-anti-gpc3-sfv-cd3%CE%B5-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/?page=2 2026-11-10 02:03:18 daily 0.8 https://www.321223.com/en/our-approach/publications/chimeric-anti-gpc3-sfv-cd3%CE%B5-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/?page=1 2026-11-10 02:02:58 daily 0.8 https://www.321223.com/en/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/?page=4 2026-11-10 02:02:38 daily 0.8 https://www.321223.com/en/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/?page=2 2026-11-10 02:02:18 daily 0.8 https://www.321223.com/en/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/?page=1 2026-11-10 02:01:58 daily 0.8 https://www.321223.com/en/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/ 2026-11-10 02:01:38 daily 0.8 https://www.321223.com/en/our-approach/publications/?page=5 2026-11-10 02:01:18 daily 0.8 https://www.321223.com/en/our-approach/publications/?page=4 2026-11-10 02:00:58 daily 0.8 https://www.321223.com/en/our-approach/publications/?page=3 2026-11-10 02:00:38 daily 0.8 https://www.321223.com/en/our-approach/publications/?page=2 2026-11-10 02:00:18 daily 0.8 https://www.321223.com/en/our-approach/publications/?page=1 2026-11-10 01:59:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20261001/ 2026-11-10 01:59:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20260918/?page=5 2026-11-10 01:59:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20260918/?page=4 2026-11-10 01:58:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20260918/?page=2 2026-11-10 01:58:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20260918/?page=1 2026-11-10 01:58:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20260918/ 2026-11-10 01:57:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20251029/?page=5 2026-11-10 01:57:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20251029/?page=4 2026-11-10 01:57:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20251029/?page=2 2026-11-10 01:56:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20251029/?page=1 2026-11-10 01:56:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20251029/ 2026-11-10 01:56:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20251008/?page=4 2026-11-10 01:55:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20251008/?page=2 2026-11-10 01:55:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20251008/?page=1 2026-11-10 01:55:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20251008/ 2026-11-10 01:54:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20250930/?page=4 2026-11-10 01:54:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20250930/?page=2 2026-11-10 01:54:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20250930/?page=1 2026-11-10 01:53:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20250930/ 2026-11-10 01:53:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20250531/?page=5 2026-11-10 01:53:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20250531/?page=4 2026-11-10 01:52:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20250531/?page=2 2026-11-10 01:52:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20250531/?page=1 2026-11-10 01:52:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20250531/ 2026-11-10 01:51:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20240524/?page=5 2026-11-10 01:51:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20240524/?page=4 2026-11-10 01:51:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20240524/?page=2 2026-11-10 01:50:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20240524/?page=1 2026-11-10 01:50:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20240524/ 2026-11-10 01:50:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20240311/?page=5 2026-11-10 01:49:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20240311/?page=4 2026-11-10 01:49:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20240311/?page=2 2026-11-10 01:49:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20240311/?page=1 2026-11-10 01:48:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20240311/ 2026-11-10 01:48:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20240205/?page=5 2026-11-10 01:48:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20240205/?page=4 2026-11-10 01:47:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20240205/?page=2 2026-11-10 01:47:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20240205/?page=1 2026-11-10 01:47:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20240205/ 2026-11-10 01:46:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20230920/?page=4 2026-11-10 01:46:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20230920/?page=2 2026-11-10 01:46:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20230920/?page=1 2026-11-10 01:45:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20230920/ 2026-11-10 01:45:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20230909/?page=5 2026-11-10 01:45:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20230909/?page=4 2026-11-10 01:44:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20230909/?page=2 2026-11-10 01:44:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20230909/?page=1 2026-11-10 01:44:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20230909/ 2026-11-10 01:43:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20230830/?page=5 2026-11-10 01:43:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20230830/?page=4 2026-11-10 01:43:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20230830/?page=2 2026-11-10 01:42:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20230830/?page=1 2026-11-10 01:42:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20230830/ 2026-11-10 01:42:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20221215/?page=4 2026-11-10 01:41:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20221215/?page=2 2026-11-10 01:41:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20221215/?page=1 2026-11-10 01:41:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20221215/ 2026-11-10 01:40:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20220817/?page=4 2026-11-10 01:40:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20220817/?page=2 2026-11-10 01:40:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20220817/?page=1 2026-11-10 01:39:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20220817/ 2026-11-10 01:39:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20201001/?page=5 2026-11-10 01:39:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20201001/?page=4 2026-11-10 01:38:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20201001/?page=2 2026-11-10 01:38:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20201001/?page=1 2026-11-10 01:38:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20201001/ 2026-11-10 01:37:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20200925/ 2026-11-10 01:37:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20200801/?page=4 2026-11-10 01:37:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20200801/?page=2 2026-11-10 01:36:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20200801/?page=1 2026-11-10 01:36:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20200801/ 2026-11-10 01:36:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20200121/?page=4 2026-11-10 01:35:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20200121/?page=2 2026-11-10 01:35:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20200121/?page=1 2026-11-10 01:35:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20200121/ 2026-11-10 01:34:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20191219/?page=4 2026-11-10 01:34:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20191219/?page=2 2026-11-10 01:34:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20191219/?page=1 2026-11-10 01:33:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20191219/ 2026-11-10 01:33:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20190920/?page=5 2026-11-10 01:33:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20190920/?page=4 2026-11-10 01:32:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20190920/?page=2 2026-11-10 01:32:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20190920/?page=1 2026-11-10 01:32:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20190920/ 2026-11-10 01:31:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20190701/?page=4 2026-11-10 01:31:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20190701/?page=2 2026-11-10 01:31:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20190701/?page=1 2026-11-10 01:30:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20190701/ 2026-11-10 01:30:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20190429/ 2026-11-10 01:30:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20190417/?page=4 2026-11-10 01:29:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20190417/?page=2 2026-11-10 01:29:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20190417/?page=1 2026-11-10 01:29:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20190417/ 2026-11-10 01:28:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20181101/?page=5 2026-11-10 01:28:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20181101/?page=4 2026-11-10 01:28:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20181101/?page=2 2026-11-10 01:27:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20181101/?page=1 2026-11-10 01:27:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20181101/ 2026-11-10 01:27:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20181001/?page=5 2026-11-10 01:26:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20181001/?page=4 2026-11-10 01:26:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20181001/?page=2 2026-11-10 01:26:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20181001/?page=1 2026-11-10 01:25:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20181001/ 2026-11-10 01:25:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20180906/ 2026-11-10 01:25:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20180804/?page=4 2026-11-10 01:24:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20180804/?page=2 2026-11-10 01:24:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20180804/?page=1 2026-11-10 01:24:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20180804/ 2026-11-10 01:23:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20171218/?page=4 2026-11-10 01:23:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20171218/?page=2 2026-11-10 01:23:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20171218/?page=1 2026-11-10 01:22:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20171218/ 2026-11-10 01:22:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20170919/?page=4 2026-11-10 01:22:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20170919/?page=2 2026-11-10 01:21:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20170919/?page=1 2026-11-10 01:21:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20170919/ 2026-11-10 01:21:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20170703/?page=5 2026-11-10 01:20:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20170703/?page=4 2026-11-10 01:20:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20170703/?page=2 2026-11-10 01:20:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20170703/?page=1 2026-11-10 01:19:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20170703/ 2026-11-10 01:19:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20170516/?page=4 2026-11-10 01:19:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20170516/?page=2 2026-11-10 01:18:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20170516/?page=1 2026-11-10 01:18:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20170516/ 2026-11-10 01:18:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20161229/?page=5 2026-11-10 01:17:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20161229/?page=4 2026-11-10 01:17:38 daily 0.8 https://www.321223.com/en/our-approach/publications/20161229/?page=2 2026-11-10 01:17:18 daily 0.8 https://www.321223.com/en/our-approach/publications/20161229/?page=1 2026-11-10 01:16:58 daily 0.8 https://www.321223.com/en/our-approach/publications/20161229/ 2026-11-10 01:16:38 daily 0.8 https://www.321223.com/en/our-approach/publications/ 2026-11-10 01:16:18 daily 0.8 https://www.321223.com/en/our-approach/manufacturing/ 2026-11-10 01:15:58 daily 0.8 https://www.321223.com/en/our-approach/ 2026-11-10 01:15:38 daily 0.8 https://www.321223.com/en/news/?page=2 2026-11-10 01:15:18 daily 0.8 https://www.321223.com/en/news/?page=13 2026-11-10 01:14:58 daily 0.8 https://www.321223.com/en/news/?page=1 2026-11-10 01:14:38 daily 0.8 https://www.321223.com/en/news/20261026/ 2026-11-10 01:14:18 daily 0.8 https://www.321223.com/en/news/20261013/ 2026-11-10 01:13:58 daily 0.8 https://www.321223.com/en/news/20260929/ 2026-11-10 01:13:38 daily 0.8 https://www.321223.com/en/news/20260819/ 2026-11-10 01:13:18 daily 0.8 https://www.321223.com/en/news/20260807/ 2026-11-10 01:12:58 daily 0.8 https://www.321223.com/en/news/20260804/ 2026-11-10 01:12:38 daily 0.8 https://www.321223.com/en/news/20260715/ 2026-11-10 01:12:18 daily 0.8 https://www.321223.com/en/news/20260622/ 2026-11-10 01:11:58 daily 0.8 https://www.321223.com/en/news/20260615/ 2026-11-10 01:11:38 daily 0.8 https://www.321223.com/en/news/20260601/ 2026-11-10 01:11:18 daily 0.8 https://www.321223.com/en/news/20260521/ 2026-11-10 01:10:58 daily 0.8 https://www.321223.com/en/news/20260512/ 2026-11-10 01:10:38 daily 0.8 https://www.321223.com/en/news/20260428/ 2026-11-10 01:10:18 daily 0.8 https://www.321223.com/en/news/20260309/ 2026-11-10 01:09:58 daily 0.8 https://www.321223.com/en/news/20260306/ 2026-11-10 01:09:38 daily 0.8 https://www.321223.com/en/news/20260213/ 2026-11-10 01:09:18 daily 0.8 https://www.321223.com/en/news/20260112/ 2026-11-10 01:08:58 daily 0.8 https://www.321223.com/en/news/20251229/ 2026-11-10 01:08:38 daily 0.8 https://www.321223.com/en/news/20250625/ 2026-11-10 01:08:18 daily 0.8 https://www.321223.com/en/news/20250120/ 2026-11-10 01:07:58 daily 0.8 https://www.321223.com/en/news/20250113/ 2026-11-10 01:07:38 daily 0.8 https://www.321223.com/en/news/20241231/ 2026-11-10 01:07:18 daily 0.8 https://www.321223.com/en/news/2023-08-21/ 2026-11-10 01:06:58 daily 0.8 https://www.321223.com/en/news/20190129/ 2026-11-10 01:06:38 daily 0.8 https://www.321223.com/en/news/ 2026-11-10 01:06:18 daily 0.8 https://www.321223.com/en/investors/listing-documents/ 2026-11-10 01:05:58 daily 0.8 https://www.321223.com/en/investors/ir-contact/ 2026-11-10 01:05:38 daily 0.8 https://www.321223.com/en/investors/financial-reports/ 2026-11-10 01:05:18 daily 0.8 https://www.321223.com/en/investors/corporate-governance/ 2026-11-10 01:04:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/webcasts/?page=6 2026-11-10 01:04:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/webcasts/?page=5 2026-11-10 01:04:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/webcasts/?page=4 2026-11-10 01:03:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/webcasts/?page=3 2026-11-10 01:03:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/webcasts/?page=2 2026-11-10 01:03:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/webcasts/?page=1 2026-11-10 01:02:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/webcasts/ 2026-11-10 01:02:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/positive-clinical-data-for-allogeneic-car-t-products-ct0596-and-ct1190b/?page=6 2026-11-10 01:02:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/positive-clinical-data-for-allogeneic-car-t-products-ct0596-and-ct1190b/?page=5 2026-11-10 01:01:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/positive-clinical-data-for-allogeneic-car-t-products-ct0596-and-ct1190b/?page=4 2026-11-10 01:01:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/positive-clinical-data-for-allogeneic-car-t-products-ct0596-and-ct1190b/?page=3 2026-11-10 01:01:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/positive-clinical-data-for-allogeneic-car-t-products-ct0596-and-ct1190b/?page=2 2026-11-10 01:00:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/positive-clinical-data-for-allogeneic-car-t-products-ct0596-and-ct1190b/?page=1 2026-11-10 01:00:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/positive-clinical-data-for-allogeneic-car-t-products-ct0596-and-ct1190b/ 2026-11-10 01:00:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/?page=6 2026-11-10 00:59:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/?page=5 2026-11-10 00:59:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/?page=4 2026-11-10 00:59:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/?page=3 2026-11-10 00:58:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/?page=2 2026-11-10 00:58:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/?page=1 2026-11-10 00:58:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20261026/ 2026-11-10 00:57:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20260601/?page=5 2026-11-10 00:57:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20260601/?page=4 2026-11-10 00:57:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20260601/?page=3 2026-11-10 00:56:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20260601/?page=2 2026-11-10 00:56:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20260601/?page=1 2026-11-10 00:56:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20260601/ 2026-11-10 00:55:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=5 2026-11-10 00:55:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=4 2026-11-10 00:55:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=3 2026-11-10 00:54:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=2 2026-11-10 00:54:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=1 2026-11-10 00:54:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/ 2026-11-10 00:53:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=6 2026-11-10 00:53:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=5 2026-11-10 00:53:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=4 2026-11-10 00:52:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=3 2026-11-10 00:52:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=2 2026-11-10 00:52:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=1 2026-11-10 00:51:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/ 2026-11-10 00:51:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251207/?page=6 2026-11-10 00:51:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251207/?page=5 2026-11-10 00:50:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251207/?page=4 2026-11-10 00:50:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251207/?page=3 2026-11-10 00:50:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251207/?page=2 2026-11-10 00:49:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251207/?page=1 2026-11-10 00:49:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251207/ 2026-11-10 00:49:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251119/?page=5 2026-11-10 00:48:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251119/?page=4 2026-11-10 00:48:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251119/?page=3 2026-11-10 00:48:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251119/?page=2 2026-11-10 00:47:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251119/?page=1 2026-11-10 00:47:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251119/ 2026-11-10 00:47:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=6 2026-11-10 00:46:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=5 2026-11-10 00:46:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=4 2026-11-10 00:46:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=3 2026-11-10 00:45:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=2 2026-11-10 00:45:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=1 2026-11-10 00:45:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/ 2026-11-10 00:44:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=6 2026-11-10 00:44:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=5 2026-11-10 00:44:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=4 2026-11-10 00:43:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=3 2026-11-10 00:43:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=2 2026-11-10 00:43:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=1 2026-11-10 00:42:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/ 2026-11-10 00:42:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=6 2026-11-10 00:42:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=5 2026-11-10 00:41:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=4 2026-11-10 00:41:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=3 2026-11-10 00:41:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=2 2026-11-10 00:40:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=1 2026-11-10 00:40:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/ 2026-11-10 00:40:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-asco-claudin18-2-specific-car-t-cells-satri-cel-versus-treatment-of-physician-s-choice-tpc-for-previously-treated-advanced-gastric-or-gastroesophageal-junction-cancer-g-gejc-primary-results-from-a-randomized-open-label-phase-ii-trial-c/ 2026-11-10 00:39:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20240119/?page=6 2026-11-10 00:39:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20240119/?page=5 2026-11-10 00:39:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20240119/?page=4 2026-11-10 00:38:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20240119/?page=3 2026-11-10 00:38:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20240119/?page=2 2026-11-10 00:38:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20240119/?page=1 2026-11-10 00:37:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20240119/ 2026-11-10 00:37:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=5 2026-11-10 00:37:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=4 2026-11-10 00:36:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=3 2026-11-10 00:36:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=2 2026-11-10 00:36:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=1 2026-11-10 00:35:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/ 2026-11-10 00:35:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=5 2026-11-10 00:35:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=4 2026-11-10 00:34:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=3 2026-11-10 00:34:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=2 2026-11-10 00:34:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=1 2026-11-10 00:33:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/ 2026-11-10 00:33:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=5 2026-11-10 00:33:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=4 2026-11-10 00:32:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=3 2026-11-10 00:32:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=2 2026-11-10 00:32:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=1 2026-11-10 00:31:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/ 2026-11-10 00:31:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=5 2026-11-10 00:31:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=4 2026-11-10 00:30:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=3 2026-11-10 00:30:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=2 2026-11-10 00:30:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=1 2026-11-10 00:29:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/ 2026-11-10 00:29:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=6 2026-11-10 00:29:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=5 2026-11-10 00:28:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=4 2026-11-10 00:28:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=3 2026-11-10 00:28:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=2 2026-11-10 00:27:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=1 2026-11-10 00:27:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/ 2026-11-10 00:27:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-asco-claudin18-2-targeted-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-gastrointestinal-cancers-final-results-of-ct041-cg4006-phase-1-trial/ 2026-11-10 00:26:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20231212/?page=6 2026-11-10 00:26:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20231212/?page=5 2026-11-10 00:26:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20231212/?page=4 2026-11-10 00:25:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20231212/?page=3 2026-11-10 00:25:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20231212/?page=2 2026-11-10 00:25:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20231212/?page=1 2026-11-10 00:24:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20231212/ 2026-11-10 00:24:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=6 2026-11-10 00:24:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=5 2026-11-10 00:23:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=4 2026-11-10 00:23:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=3 2026-11-10 00:23:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=2 2026-11-10 00:22:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=1 2026-11-10 00:22:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/ 2026-11-10 00:22:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-gi-a-multicenter-phase-1-study-of-ab011-a-recombinant-humanized-anti-cldn18-2-monoclonal-antibody-ab011-as-monotherapy-and-combined-with-capecitabine-and-oxaliplatin-capox-in-patients-with-advanced-solid-tumors/ 2026-11-10 00:21:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=6 2026-11-10 00:21:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=5 2026-11-10 00:21:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=4 2026-11-10 00:20:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=3 2026-11-10 00:20:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=2 2026-11-10 00:20:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=1 2026-11-10 00:19:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-2/ 2026-11-10 00:19:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=5 2026-11-10 00:19:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=4 2026-11-10 00:18:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=3 2026-11-10 00:18:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=2 2026-11-10 00:18:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=1 2026-11-10 00:17:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-1/ 2026-11-10 00:17:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-aacr/?page=6 2026-11-10 00:17:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-aacr/?page=5 2026-11-10 00:16:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-aacr/?page=4 2026-11-10 00:16:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-aacr/?page=3 2026-11-10 00:16:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-aacr/?page=2 2026-11-10 00:15:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-aacr/?page=1 2026-11-10 00:15:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-aacr/ 2026-11-10 00:15:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=6 2026-11-10 00:14:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=5 2026-11-10 00:14:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=4 2026-11-10 00:14:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=3 2026-11-10 00:13:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=2 2026-11-10 00:13:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=1 2026-11-10 00:13:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/ 2026-11-10 00:12:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=6 2026-11-10 00:12:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=5 2026-11-10 00:12:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=4 2026-11-10 00:11:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=3 2026-11-10 00:11:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=2 2026-11-10 00:11:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=1 2026-11-10 00:10:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/ 2026-11-10 00:10:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=5 2026-11-10 00:10:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=4 2026-11-10 00:09:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=3 2026-11-10 00:09:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=2 2026-11-10 00:09:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=1 2026-11-10 00:08:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/ 2026-11-10 00:08:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=6 2026-11-10 00:08:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=5 2026-11-10 00:07:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=4 2026-11-10 00:07:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=3 2026-11-10 00:07:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=2 2026-11-10 00:06:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=1 2026-11-10 00:06:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/ 2026-11-10 00:06:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=6 2026-11-10 00:05:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=5 2026-11-10 00:05:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=4 2026-11-10 00:05:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=3 2026-11-10 00:04:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=2 2026-11-10 00:04:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=1 2026-11-10 00:04:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/ 2026-11-10 00:03:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=6 2026-11-10 00:03:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=5 2026-11-10 00:03:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=4 2026-11-10 00:02:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=3 2026-11-10 00:02:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=2 2026-11-10 00:02:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=1 2026-11-10 00:01:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/ 2026-11-10 00:01:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=6 2026-11-10 00:01:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=5 2026-11-10 00:00:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=4 2026-11-10 00:00:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=3 2026-11-10 00:00:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=2 2026-11-09 23:59:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=1 2026-11-09 23:59:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/ 2026-11-09 23:59:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/ 2026-11-09 23:58:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/corporate-deck/?page=5 2026-11-09 23:58:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/corporate-deck/?page=4 2026-11-09 23:57:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/corporate-deck/?page=3 2026-11-09 23:57:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/corporate-deck/?page=2 2026-11-09 23:57:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/corporate-deck/?page=1 2026-11-09 23:56:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/corporate-deck/ 2026-11-09 23:56:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/?page=5 2026-11-09 23:56:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/?page=4 2026-11-09 23:55:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/?page=3 2026-11-09 23:55:38 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/?page=2 2026-11-09 23:55:18 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/?page=1 2026-11-09 23:54:58 daily 0.8 https://www.321223.com/en/investors/corporate-deck-presentations/ 2026-11-09 23:54:38 daily 0.8 https://www.321223.com/en/investors/announcements-circulars/ 2026-11-09 23:54:18 daily 0.8 https://www.321223.com/en/investors/ 2026-11-09 23:53:58 daily 0.8 https://www.321223.com/en/disclaimer/ 2026-11-09 23:53:38 daily 0.8 https://www.321223.com/en/contact-us/ 2026-11-09 23:53:18 daily 0.8 https://www.321223.com/en/careers/join-us/ 2026-11-09 23:52:58 daily 0.8 https://www.321223.com/en/careers/ 2026-11-09 23:52:38 daily 0.8 https://www.321223.com/en/about-us/vision-mission-values/ 2026-11-09 23:52:18 daily 0.8 https://www.321223.com/en/about-us/partnering/ 2026-11-09 23:51:58 daily 0.8 https://www.321223.com/en/about-us/leadership/ 2026-11-09 23:51:38 daily 0.8 https://www.321223.com/en/about-us/company-overview/ 2026-11-09 23:51:18 daily 0.8 https://www.321223.com/en/about-us/ 2026-11-09 23:50:58 daily 0.8 https://www.321223.com/en/" 2026-11-09 23:50:38 daily 0.8 https://www.321223.com/en/ 2026-11-09 23:50:18 daily 0.8 https://www.321223.com/cpzs/html/179.html 2026-11-09 23:49:58 daily 0.8 https://www.321223.com/cpzs/html/178.html 2026-11-09 23:49:38 daily 0.8 https://www.321223.com/cpzs/html/177.html 2026-11-09 23:49:18 daily 0.8 https://www.321223.com/cpzs/html/176.html 2026-11-09 23:48:58 daily 0.8 https://www.321223.com/cpzs/html/174.html 2026-11-09 23:48:38 daily 0.8 https://www.321223.com/cpzs/html/173.html 2026-11-09 23:48:18 daily 0.8 https://www.321223.com/cpzs/html/172.html 2026-11-09 23:47:58 daily 0.8 https://www.321223.com/cpzs/html/171.html 2026-11-09 23:47:38 daily 0.8 https://www.321223.com/cpzs/html/170.html 2026-11-09 23:47:18 daily 0.8 https://www.321223.com/cpzs/html/169.html 2026-11-09 23:46:58 daily 0.8 https://www.321223.com/cpzs/html/168.html 2026-11-09 23:46:38 daily 0.8 https://www.321223.com/cpzs/html/167.html 2026-11-09 23:46:18 daily 0.8 https://www.321223.com/cpzs/html/166.html 2026-11-09 23:45:58 daily 0.8 https://www.321223.com/cpzs/ 2026-11-09 23:45:38 daily 0.8 https://www.321223.com/cn/privacy-policy/ 2026-11-09 23:44:58 daily 0.8 https://www.321223.com/cn/pipeline/zevor-cel/ 2026-11-09 23:44:18 daily 0.8 https://www.321223.com/cn/pipeline/satri-cel/ 2026-11-09 23:43:38 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/mab/kj-c2630/ 2026-11-09 23:42:58 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/mab/kj-c2527/ 2026-11-09 23:42:18 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/mab/kj-c2526/ 2026-11-09 23:41:38 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/mab/ct1390b/ 2026-11-09 23:40:58 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/mab/ct1190b-kj-c2219/ 2026-11-09 23:40:18 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/mab/ct0596/ 2026-11-09 23:39:38 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/mab/ 2026-11-09 23:38:58 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/in-vivo-car-t/kj-c2635/ 2026-11-09 23:38:18 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/in-vivo-car-t/kj-c2634/ 2026-11-09 23:37:38 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/in-vivo-car-t/kj-c2633/ 2026-11-09 23:36:58 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/in-vivo-car-t/kj-c2632/ 2026-11-09 23:36:18 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/in-vivo-car-t/kj-c2529/ 2026-11-09 23:35:38 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/in-vivo-car-t/ 2026-11-09 23:34:58 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/car-t-cell-therapies/zevor-cel-ct053-3/ 2026-11-09 23:34:18 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/car-t-cell-therapies/ct041/ 2026-11-09 23:33:38 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/car-t-cell-therapies/ 2026-11-09 23:32:58 daily 0.8 https://www.321223.com/cn/pipeline/new-pipeline/ 2026-11-09 23:32:18 daily 0.8 https://www.321223.com/cn/pipeline/expanded-access/ 2026-11-09 23:31:58 daily 0.8 https://www.321223.com/cn/pipeline/ 2026-11-09 23:31:18 daily 0.8 https://www.321223.com/cn/our-approach/technologies/ 2026-11-09 23:30:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/zevorcabtagene-autoleucel-first-approval/?page=5 2026-11-09 23:30:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/zevorcabtagene-autoleucel-first-approval/?page=4 2026-11-09 23:29:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/zevorcabtagene-autoleucel-first-approval/?page=2 2026-11-09 23:29:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/zevorcabtagene-autoleucel-first-approval/?page=1 2026-11-09 23:29:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/zevorcabtagene-autoleucel-first-approval/ 2026-11-09 23:28:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-κb-icam1-signaling/ 2026-11-09 23:27:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-��b-icam1-signaling/ 2026-11-09 23:27:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-%CE%BAb-icam1-signaling/?page=5 2026-11-09 23:27:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-%CE%BAb-icam1-signaling/?page=4 2026-11-09 23:26:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-%CE%BAb-icam1-signaling/?page=2 2026-11-09 23:26:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-%CE%BAb-icam1-signaling/?page=1 2026-11-09 23:26:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/?page=4 2026-11-09 23:25:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/?page=2 2026-11-09 23:25:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/?page=1 2026-11-09 23:25:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/ 2026-11-09 23:24:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/?page=5 2026-11-09 23:24:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/?page=4 2026-11-09 23:23:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/?page=2 2026-11-09 23:23:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/?page=1 2026-11-09 23:23:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/ 2026-11-09 23:22:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/combined-local-therapy-and-car-gpc3/?page=5 2026-11-09 23:22:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/combined-local-therapy-and-car-gpc3/?page=4 2026-11-09 23:21:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/combined-local-therapy-and-car-gpc3/?page=2 2026-11-09 23:21:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/combined-local-therapy-and-car-gpc3/?page=1 2026-11-09 23:21:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/combined-local-therapy-and-car-gpc3/ 2026-11-09 23:20:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/?page=5 2026-11-09 23:20:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/?page=4 2026-11-09 23:19:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/?page=2 2026-11-09 23:19:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/?page=1 2026-11-09 23:19:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/ 2026-11-09 23:18:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/?page=5 2026-11-09 23:18:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/?page=4 2026-11-09 23:17:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/?page=2 2026-11-09 23:17:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/?page=1 2026-11-09 23:17:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/ 2026-11-09 23:16:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/chimeric-anti-gpc3-sfv-cd3ε-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/ 2026-11-09 23:15:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/chimeric-anti-gpc3-sfv-cd3��-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/ 2026-11-09 23:15:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/chimeric-anti-gpc3-sfv-cd3%CE%B5-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/?page=4 2026-11-09 23:15:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/chimeric-anti-gpc3-sfv-cd3%CE%B5-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/?page=2 2026-11-09 23:14:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/chimeric-anti-gpc3-sfv-cd3%CE%B5-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/?page=1 2026-11-09 23:14:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/?page=5 2026-11-09 23:14:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/?page=4 2026-11-09 23:13:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/?page=2 2026-11-09 23:13:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/?page=1 2026-11-09 23:13:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/ 2026-11-09 23:12:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/?page=5 2026-11-09 23:12:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/?page=4 2026-11-09 23:11:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/?page=3 2026-11-09 23:11:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/?page=2 2026-11-09 23:11:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/?page=1 2026-11-09 23:10:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20261001/ 2026-11-09 23:10:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20260918/?page=4 2026-11-09 23:09:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20260918/?page=2 2026-11-09 23:09:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20260918/?page=1 2026-11-09 23:09:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20260918/ 2026-11-09 23:08:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20251029/?page=4 2026-11-09 23:08:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20251029/?page=2 2026-11-09 23:07:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20251029/?page=1 2026-11-09 23:07:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20251029/ 2026-11-09 23:06:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20251008/?page=4 2026-11-09 23:06:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20251008/?page=2 2026-11-09 23:06:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20251008/?page=1 2026-11-09 23:05:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20251008/ 2026-11-09 23:05:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20250930/?page=5 2026-11-09 23:04:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20250930/?page=4 2026-11-09 23:04:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20250930/?page=2 2026-11-09 23:04:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20250930/?page=1 2026-11-09 23:03:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20250930/ 2026-11-09 23:03:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20250531/?page=5 2026-11-09 23:02:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20250531/?page=4 2026-11-09 23:02:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20250531/?page=2 2026-11-09 23:02:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20250531/?page=1 2026-11-09 23:01:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20250531/ 2026-11-09 23:01:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240524/?page=5 2026-11-09 23:00:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240524/?page=4 2026-11-09 23:00:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240524/?page=2 2026-11-09 23:00:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240524/?page=1 2026-11-09 22:59:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240524/ 2026-11-09 22:59:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240311/?page=4 2026-11-09 22:58:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240311/?page=2 2026-11-09 22:58:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240311/?page=1 2026-11-09 22:58:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240311/ 2026-11-09 22:57:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240205/?page=5 2026-11-09 22:57:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240205/?page=4 2026-11-09 22:56:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240205/?page=2 2026-11-09 22:56:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240205/?page=1 2026-11-09 22:56:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20240205/ 2026-11-09 22:55:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230920/?page=5 2026-11-09 22:55:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230920/?page=4 2026-11-09 22:54:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230920/?page=2 2026-11-09 22:54:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230920/?page=1 2026-11-09 22:54:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230920/ 2026-11-09 22:53:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230909/?page=5 2026-11-09 22:53:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230909/?page=4 2026-11-09 22:52:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230909/?page=2 2026-11-09 22:52:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230909/?page=1 2026-11-09 22:52:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230909/ 2026-11-09 22:51:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230830/?page=4 2026-11-09 22:51:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230830/?page=2 2026-11-09 22:50:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230830/?page=1 2026-11-09 22:50:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20230830/ 2026-11-09 22:49:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20221215/?page=5 2026-11-09 22:49:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20221215/?page=4 2026-11-09 22:49:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20221215/?page=2 2026-11-09 22:48:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20221215/?page=1 2026-11-09 22:48:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20221215/ 2026-11-09 22:47:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20220817/?page=4 2026-11-09 22:47:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20220817/?page=2 2026-11-09 22:47:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20220817/?page=1 2026-11-09 22:46:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20220817/ 2026-11-09 22:46:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20201001/?page=5 2026-11-09 22:45:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20201001/?page=4 2026-11-09 22:45:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20201001/?page=2 2026-11-09 22:45:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20201001/?page=1 2026-11-09 22:44:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20201001/ 2026-11-09 22:44:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200925/?page=5 2026-11-09 22:43:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200925/?page=4 2026-11-09 22:43:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200925/?page=2 2026-11-09 22:43:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200925/?page=1 2026-11-09 22:42:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200925/ 2026-11-09 22:42:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200801/?page=4 2026-11-09 22:41:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200801/?page=2 2026-11-09 22:41:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200801/?page=1 2026-11-09 22:41:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200801/ 2026-11-09 22:40:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200121/?page=5 2026-11-09 22:40:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200121/?page=4 2026-11-09 22:39:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200121/?page=2 2026-11-09 22:39:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200121/?page=1 2026-11-09 22:39:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20200121/ 2026-11-09 22:38:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20191219/?page=5 2026-11-09 22:38:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20191219/?page=4 2026-11-09 22:37:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20191219/?page=2 2026-11-09 22:37:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20191219/?page=1 2026-11-09 22:37:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20191219/ 2026-11-09 22:36:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190920/?page=5 2026-11-09 22:36:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190920/?page=4 2026-11-09 22:35:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190920/?page=2 2026-11-09 22:35:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190920/?page=1 2026-11-09 22:35:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190920/ 2026-11-09 22:34:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190701/?page=4 2026-11-09 22:34:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190701/?page=2 2026-11-09 22:33:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190701/?page=1 2026-11-09 22:33:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190701/ 2026-11-09 22:32:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190429/?page=5 2026-11-09 22:32:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190429/?page=4 2026-11-09 22:32:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190429/?page=2 2026-11-09 22:31:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190429/?page=1 2026-11-09 22:31:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190429/ 2026-11-09 22:30:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190417/?page=4 2026-11-09 22:30:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190417/?page=2 2026-11-09 22:30:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190417/?page=1 2026-11-09 22:29:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20190417/ 2026-11-09 22:29:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20181101/?page=5 2026-11-09 22:28:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20181101/?page=4 2026-11-09 22:28:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20181101/?page=2 2026-11-09 22:28:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20181101/?page=1 2026-11-09 22:27:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20181101/ 2026-11-09 22:27:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20181001/?page=4 2026-11-09 22:26:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20181001/?page=2 2026-11-09 22:26:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20181001/?page=1 2026-11-09 22:26:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20181001/ 2026-11-09 22:25:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20180906/?page=4 2026-11-09 22:25:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20180906/?page=2 2026-11-09 22:24:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20180906/?page=1 2026-11-09 22:24:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20180906/ 2026-11-09 22:23:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20180804/?page=4 2026-11-09 22:23:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20180804/?page=2 2026-11-09 22:23:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20180804/?page=1 2026-11-09 22:22:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20180804/ 2026-11-09 22:22:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20171218/?page=5 2026-11-09 22:21:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20171218/?page=4 2026-11-09 22:21:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20171218/?page=2 2026-11-09 22:21:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20171218/?page=1 2026-11-09 22:20:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20171218/ 2026-11-09 22:20:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170919/?page=5 2026-11-09 22:19:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170919/?page=4 2026-11-09 22:19:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170919/?page=2 2026-11-09 22:19:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170919/?page=1 2026-11-09 22:18:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170919/ 2026-11-09 22:18:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170703/?page=5 2026-11-09 22:17:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170703/?page=4 2026-11-09 22:17:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170703/?page=2 2026-11-09 22:17:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170703/?page=1 2026-11-09 22:16:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170703/ 2026-11-09 22:16:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170516/?page=4 2026-11-09 22:15:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170516/?page=2 2026-11-09 22:15:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170516/?page=1 2026-11-09 22:15:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20170516/ 2026-11-09 22:14:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20161229/?page=4 2026-11-09 22:14:18 daily 0.8 https://www.321223.com/cn/our-approach/publications/20161229/?page=2 2026-11-09 22:13:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/20161229/?page=1 2026-11-09 22:13:38 daily 0.8 https://www.321223.com/cn/our-approach/publications/20161229/ 2026-11-09 22:12:58 daily 0.8 https://www.321223.com/cn/our-approach/publications/ 2026-11-09 22:12:18 daily 0.8 https://www.321223.com/cn/our-approach/manufacturing/ 2026-11-09 22:11:38 daily 0.8 https://www.321223.com/cn/our-approach/ 2026-11-09 22:10:58 daily 0.8 https://www.321223.com/cn/news/?page=4 2026-11-09 22:10:38 daily 0.8 https://www.321223.com/cn/news/?page=3 2026-11-09 22:10:18 daily 0.8 https://www.321223.com/cn/news/?page=21 2026-11-09 22:09:58 daily 0.8 https://www.321223.com/cn/news/?page=20 2026-11-09 22:09:38 daily 0.8 https://www.321223.com/cn/news/?page=2 2026-11-09 22:09:18 daily 0.8 https://www.321223.com/cn/news/?page=19 2026-11-09 22:08:58 daily 0.8 https://www.321223.com/cn/news/?page=18 2026-11-09 22:08:38 daily 0.8 https://www.321223.com/cn/news/?page=1 2026-11-09 22:08:18 daily 0.8 https://www.321223.com/cn/news/20261009/ 2026-11-09 22:07:58 daily 0.8 https://www.321223.com/cn/news/20260929/ 2026-11-09 22:07:38 daily 0.8 https://www.321223.com/cn/news/20260921/ 2026-11-09 22:07:18 daily 0.8 https://www.321223.com/cn/news/20260914/ 2026-11-09 22:06:58 daily 0.8 https://www.321223.com/cn/news/20260819/ 2026-11-09 22:06:38 daily 0.8 https://www.321223.com/cn/news/20260807/ 2026-11-09 22:06:18 daily 0.8 https://www.321223.com/cn/news/20260804/ 2026-11-09 22:05:58 daily 0.8 https://www.321223.com/cn/news/20260724/ 2026-11-09 22:05:38 daily 0.8 https://www.321223.com/cn/news/20260722/ 2026-11-09 22:05:18 daily 0.8 https://www.321223.com/cn/news/20260716/ 2026-11-09 22:04:58 daily 0.8 https://www.321223.com/cn/news/20260715/ 2026-11-09 22:04:38 daily 0.8 https://www.321223.com/cn/news/20260707/ 2026-11-09 22:04:18 daily 0.8 https://www.321223.com/cn/news/20260622/ 2026-11-09 22:03:58 daily 0.8 https://www.321223.com/cn/news/20260622-1/ 2026-11-09 22:03:38 daily 0.8 https://www.321223.com/cn/news/20260615/ 2026-11-09 22:03:18 daily 0.8 https://www.321223.com/cn/news/20260601/ 2026-11-09 22:02:58 daily 0.8 https://www.321223.com/cn/news/20260521/ 2026-11-09 22:02:38 daily 0.8 https://www.321223.com/cn/news/20260512/ 2026-11-09 22:02:18 daily 0.8 https://www.321223.com/cn/news/20260429/ 2026-11-09 22:01:58 daily 0.8 https://www.321223.com/cn/news/20260428/ 2026-11-09 22:01:38 daily 0.8 https://www.321223.com/cn/news/20260309/ 2026-11-09 22:01:18 daily 0.8 https://www.321223.com/cn/news/20260306/ 2026-11-09 22:00:58 daily 0.8 https://www.321223.com/cn/news/20260213/ 2026-11-09 22:00:38 daily 0.8 https://www.321223.com/cn/news/20260112/ 2026-11-09 22:00:18 daily 0.8 https://www.321223.com/cn/news/20251230/ 2026-11-09 21:59:58 daily 0.8 https://www.321223.com/cn/news/20251229/ 2026-11-09 21:59:38 daily 0.8 https://www.321223.com/cn/news/20251208/ 2026-11-09 21:59:18 daily 0.8 https://www.321223.com/cn/news/20251207/ 2026-11-09 21:58:58 daily 0.8 https://www.321223.com/cn/news/20251120/ 2026-11-09 21:58:38 daily 0.8 https://www.321223.com/cn/news/20251119/ 2026-11-09 21:58:18 daily 0.8 https://www.321223.com/cn/news/20250626/ 2026-11-09 21:57:58 daily 0.8 https://www.321223.com/cn/news/20250625/ 2026-11-09 21:57:38 daily 0.8 https://www.321223.com/cn/news/20250617/ 2026-11-09 21:57:18 daily 0.8 https://www.321223.com/cn/news/20250113/ 2026-11-09 21:56:58 daily 0.8 https://www.321223.com/cn/news/20190129/ 2026-11-09 21:56:38 daily 0.8 https://www.321223.com/cn/news/20180302/ 2026-11-09 21:56:18 daily 0.8 https://www.321223.com/cn/news/20170830/ 2026-11-09 21:55:58 daily 0.8 https://www.321223.com/cn/news/20170810/ 2026-11-09 21:55:38 daily 0.8 https://www.321223.com/cn/news/20170731/ 2026-11-09 21:55:18 daily 0.8 https://www.321223.com/cn/news/20170630/ 2026-11-09 21:54:58 daily 0.8 https://www.321223.com/cn/news/20170503/ 2026-11-09 21:54:38 daily 0.8 https://www.321223.com/cn/news/20160921/ 2026-11-09 21:54:18 daily 0.8 https://www.321223.com/cn/news/20160125/ 2026-11-09 21:53:58 daily 0.8 https://www.321223.com/cn/news/ 2026-11-09 21:53:18 daily 0.8 https://www.321223.com/cn/investors/listing-documents/ 2026-11-09 21:52:38 daily 0.8 https://www.321223.com/cn/investors/ir-contact/ 2026-11-09 21:51:58 daily 0.8 https://www.321223.com/cn/investors/financial-reports/ 2026-11-09 21:51:18 daily 0.8 https://www.321223.com/cn/investors/corporate-governance/ 2026-11-09 21:50:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/webcasts/?page=6 2026-11-09 21:50:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/webcasts/?page=5 2026-11-09 21:49:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/webcasts/?page=4 2026-11-09 21:49:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/webcasts/?page=3 2026-11-09 21:49:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/webcasts/?page=2 2026-11-09 21:48:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/webcasts/?page=1 2026-11-09 21:48:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/webcasts/ 2026-11-09 21:47:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/通用型car-t产品ct0596及ct1190b的积极临床数据/ 2026-11-09 21:47:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/ͨ����car-t��Ʒct0596��ct1190b�Ļ����ٴ�����/ 2026-11-09 21:46:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/?page=6 2026-11-09 21:46:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/?page=5 2026-11-09 21:45:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/?page=4 2026-11-09 21:45:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/?page=3 2026-11-09 21:44:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/?page=2 2026-11-09 21:43:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/?page=1 2026-11-09 21:43:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20261026/?page=6 2026-11-09 21:42:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20261026/?page=5 2026-11-09 21:42:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20261026/?page=4 2026-11-09 21:42:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20261026/?page=3 2026-11-09 21:41:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20261026/?page=2 2026-11-09 21:41:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20261026/?page=1 2026-11-09 21:41:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20261026/ 2026-11-09 21:40:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20260601/?page=6 2026-11-09 21:40:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20260601/?page=5 2026-11-09 21:39:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20260601/?page=4 2026-11-09 21:39:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20260601/?page=3 2026-11-09 21:39:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20260601/?page=2 2026-11-09 21:38:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20260601/?page=1 2026-11-09 21:38:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20260601/ 2026-11-09 21:37:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=6 2026-11-09 21:37:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=5 2026-11-09 21:37:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=4 2026-11-09 21:36:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=3 2026-11-09 21:36:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=2 2026-11-09 21:36:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=1 2026-11-09 21:35:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/ 2026-11-09 21:35:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=6 2026-11-09 21:34:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=5 2026-11-09 21:34:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=4 2026-11-09 21:34:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=3 2026-11-09 21:33:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=2 2026-11-09 21:33:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=1 2026-11-09 21:33:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/ 2026-11-09 21:32:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251207/?page=6 2026-11-09 21:32:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251207/?page=5 2026-11-09 21:31:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251207/?page=4 2026-11-09 21:31:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251207/?page=3 2026-11-09 21:31:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251207/?page=2 2026-11-09 21:30:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251207/?page=1 2026-11-09 21:30:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251207/ 2026-11-09 21:29:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251119/?page=6 2026-11-09 21:29:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251119/?page=5 2026-11-09 21:29:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251119/?page=4 2026-11-09 21:28:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251119/?page=3 2026-11-09 21:28:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251119/?page=2 2026-11-09 21:28:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251119/?page=1 2026-11-09 21:27:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251119/ 2026-11-09 21:27:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=6 2026-11-09 21:26:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=5 2026-11-09 21:26:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=4 2026-11-09 21:26:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=3 2026-11-09 21:25:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=2 2026-11-09 21:25:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=1 2026-11-09 21:25:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/ 2026-11-09 21:24:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=5 2026-11-09 21:24:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=4 2026-11-09 21:23:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=3 2026-11-09 21:23:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=2 2026-11-09 21:23:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=1 2026-11-09 21:22:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/ 2026-11-09 21:22:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=6 2026-11-09 21:21:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=5 2026-11-09 21:21:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=4 2026-11-09 21:21:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=3 2026-11-09 21:20:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=2 2026-11-09 21:20:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=1 2026-11-09 21:20:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/ 2026-11-09 21:19:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-asco-claudin18-2-specific-car-t-cells-satri-cel-versus-treatment-of-physician-s-choice-tpc-for-previously-treated-advanced-gastric-or-gastroesophageal-junction-cancer-g-gejc-primary-results-from-a-randomized-open-label-phase-ii-trial-c/ 2026-11-09 21:18:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20240119/?page=5 2026-11-09 21:18:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20240119/?page=4 2026-11-09 21:18:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20240119/?page=3 2026-11-09 21:17:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20240119/?page=2 2026-11-09 21:17:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20240119/?page=1 2026-11-09 21:17:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20240119/ 2026-11-09 21:16:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=6 2026-11-09 21:16:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=5 2026-11-09 21:15:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=4 2026-11-09 21:15:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=3 2026-11-09 21:15:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=2 2026-11-09 21:14:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=1 2026-11-09 21:14:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/ 2026-11-09 21:13:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=6 2026-11-09 21:13:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=5 2026-11-09 21:13:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=4 2026-11-09 21:12:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=3 2026-11-09 21:12:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=2 2026-11-09 21:12:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=1 2026-11-09 21:11:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/ 2026-11-09 21:11:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=6 2026-11-09 21:10:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=5 2026-11-09 21:10:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=4 2026-11-09 21:10:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=3 2026-11-09 21:09:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=2 2026-11-09 21:09:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=1 2026-11-09 21:09:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/ 2026-11-09 21:08:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=6 2026-11-09 21:08:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=5 2026-11-09 21:07:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=4 2026-11-09 21:07:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=3 2026-11-09 21:07:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=2 2026-11-09 21:06:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=1 2026-11-09 21:06:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/ 2026-11-09 21:05:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=5 2026-11-09 21:05:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=4 2026-11-09 21:05:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=3 2026-11-09 21:04:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=2 2026-11-09 21:04:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=1 2026-11-09 21:04:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/ 2026-11-09 21:03:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-asco-claudin18-2-targeted-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-gastrointestinal-cancers-final-results-of-ct041-cg4006-phase-1-trial/?page=6 2026-11-09 21:03:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-asco-claudin18-2-targeted-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-gastrointestinal-cancers-final-results-of-ct041-cg4006-phase-1-trial/?page=5 2026-11-09 21:02:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-asco-claudin18-2-targeted-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-gastrointestinal-cancers-final-results-of-ct041-cg4006-phase-1-trial/?page=4 2026-11-09 21:02:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-asco-claudin18-2-targeted-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-gastrointestinal-cancers-final-results-of-ct041-cg4006-phase-1-trial/?page=3 2026-11-09 21:02:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-asco-claudin18-2-targeted-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-gastrointestinal-cancers-final-results-of-ct041-cg4006-phase-1-trial/?page=2 2026-11-09 21:01:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-asco-claudin18-2-targeted-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-gastrointestinal-cancers-final-results-of-ct041-cg4006-phase-1-trial/?page=1 2026-11-09 21:01:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-asco-claudin18-2-targeted-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-gastrointestinal-cancers-final-results-of-ct041-cg4006-phase-1-trial/ 2026-11-09 21:00:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20231212/?page=5 2026-11-09 21:00:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20231212/?page=4 2026-11-09 21:00:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20231212/?page=3 2026-11-09 20:59:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20231212/?page=2 2026-11-09 20:59:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20231212/?page=1 2026-11-09 20:59:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20231212/ 2026-11-09 20:58:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=6 2026-11-09 20:58:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=5 2026-11-09 20:57:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=4 2026-11-09 20:57:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=3 2026-11-09 20:57:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=2 2026-11-09 20:56:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=1 2026-11-09 20:56:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/ 2026-11-09 20:55:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-gi-a-multicenter-phase-1-study-of-ab011-a-recombinant-humanized-anti-cldn18-2-monoclonal-antibody-ab011-as-monotherapy-and-combined-with-capecitabine-and-oxaliplatin-capox-in-patients-with-advanced-solid-tumors/ 2026-11-09 20:55:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=5 2026-11-09 20:54:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=4 2026-11-09 20:54:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=3 2026-11-09 20:54:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=2 2026-11-09 20:53:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=1 2026-11-09 20:53:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-2/ 2026-11-09 20:52:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=5 2026-11-09 20:52:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=4 2026-11-09 20:52:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=3 2026-11-09 20:51:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=2 2026-11-09 20:51:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=1 2026-11-09 20:51:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-1/ 2026-11-09 20:50:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-aacr/?page=5 2026-11-09 20:50:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-aacr/?page=4 2026-11-09 20:49:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-aacr/?page=3 2026-11-09 20:49:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-aacr/?page=2 2026-11-09 20:49:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-aacr/?page=1 2026-11-09 20:48:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-aacr/ 2026-11-09 20:48:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=6 2026-11-09 20:47:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=5 2026-11-09 20:47:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=4 2026-11-09 20:47:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=3 2026-11-09 20:46:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=2 2026-11-09 20:46:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=1 2026-11-09 20:46:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/ 2026-11-09 20:45:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=5 2026-11-09 20:45:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=4 2026-11-09 20:44:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=3 2026-11-09 20:44:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=2 2026-11-09 20:44:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=1 2026-11-09 20:43:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/ 2026-11-09 20:43:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=5 2026-11-09 20:42:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=4 2026-11-09 20:42:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=3 2026-11-09 20:42:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=2 2026-11-09 20:41:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=1 2026-11-09 20:41:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/ 2026-11-09 20:40:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=5 2026-11-09 20:40:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=4 2026-11-09 20:40:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=3 2026-11-09 20:39:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=2 2026-11-09 20:39:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=1 2026-11-09 20:39:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/ 2026-11-09 20:38:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=6 2026-11-09 20:38:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=5 2026-11-09 20:37:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=4 2026-11-09 20:37:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=3 2026-11-09 20:37:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=2 2026-11-09 20:36:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=1 2026-11-09 20:36:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/ 2026-11-09 20:35:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=5 2026-11-09 20:35:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=4 2026-11-09 20:35:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=3 2026-11-09 20:34:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=2 2026-11-09 20:34:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=1 2026-11-09 20:34:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/ 2026-11-09 20:33:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=5 2026-11-09 20:33:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=4 2026-11-09 20:32:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=3 2026-11-09 20:32:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=2 2026-11-09 20:32:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=1 2026-11-09 20:31:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/ 2026-11-09 20:31:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/%E9%80%9A%E7%94%A8%E5%9E%8Bcar-t%E4%BA%A7%E5%93%81ct0596%E5%8F%8Act1190b%E7%9A%84%E7%A7%AF%E6%9E%81%E4%B8%B4%E5%BA%8A%E6%95%B0%E6%8D%AE/?page=5 2026-11-09 20:30:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/%E9%80%9A%E7%94%A8%E5%9E%8Bcar-t%E4%BA%A7%E5%93%81ct0596%E5%8F%8Act1190b%E7%9A%84%E7%A7%AF%E6%9E%81%E4%B8%B4%E5%BA%8A%E6%95%B0%E6%8D%AE/?page=4 2026-11-09 20:30:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/%E9%80%9A%E7%94%A8%E5%9E%8Bcar-t%E4%BA%A7%E5%93%81ct0596%E5%8F%8Act1190b%E7%9A%84%E7%A7%AF%E6%9E%81%E4%B8%B4%E5%BA%8A%E6%95%B0%E6%8D%AE/?page=3 2026-11-09 20:30:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/%E9%80%9A%E7%94%A8%E5%9E%8Bcar-t%E4%BA%A7%E5%93%81ct0596%E5%8F%8Act1190b%E7%9A%84%E7%A7%AF%E6%9E%81%E4%B8%B4%E5%BA%8A%E6%95%B0%E6%8D%AE/?page=2 2026-11-09 20:29:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/%E9%80%9A%E7%94%A8%E5%9E%8Bcar-t%E4%BA%A7%E5%93%81ct0596%E5%8F%8Act1190b%E7%9A%84%E7%A7%AF%E6%9E%81%E4%B8%B4%E5%BA%8A%E6%95%B0%E6%8D%AE/?page=1 2026-11-09 20:29:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/ 2026-11-09 20:28:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=5 2026-11-09 20:28:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=4 2026-11-09 20:28:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=3 2026-11-09 20:27:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=2 2026-11-09 20:27:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=1 2026-11-09 20:27:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/ 2026-11-09 20:26:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/?page=5 2026-11-09 20:26:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/?page=4 2026-11-09 20:25:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/?page=3 2026-11-09 20:25:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/?page=2 2026-11-09 20:25:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/?page=1 2026-11-09 20:24:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/ 2026-11-09 20:24:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/?page=5 2026-11-09 20:23:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/?page=4 2026-11-09 20:23:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/?page=3 2026-11-09 20:23:18 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/?page=2 2026-11-09 20:22:58 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/?page=1 2026-11-09 20:22:38 daily 0.8 https://www.321223.com/cn/investors/corporate-deck-presentations/ 2026-11-09 20:21:58 daily 0.8 https://www.321223.com/cn/investors/announcements-circulars/ 2026-11-09 20:21:18 daily 0.8 https://www.321223.com/cn/investors/ 2026-11-09 20:20:38 daily 0.8 https://www.321223.com/cn/disclaimer/ 2026-11-09 20:19:58 daily 0.8 https://www.321223.com/cn/contact-us/ 2026-11-09 20:19:18 daily 0.8 https://www.321223.com/cn/careers/join-us/ 2026-11-09 20:18:38 daily 0.8 https://www.321223.com/cn/careers/ 2026-11-09 20:17:58 daily 0.8 https://www.321223.com/cn/about-us/vision-mission-values/ 2026-11-09 20:17:18 daily 0.8 https://www.321223.com/cn/about-us/partnering/ 2026-11-09 20:16:38 daily 0.8 https://www.321223.com/cn/about-us/leadership/ 2026-11-09 20:15:58 daily 0.8 https://www.321223.com/cn/about-us/company-overview/ 2026-11-09 20:15:18 daily 0.8 https://www.321223.com/cn/about-us/ 2026-11-09 20:14:38 daily 0.8 https://www.321223.com/cn/" 2026-11-09 20:14:18 daily 0.8 https://www.321223.com/cn/ 2026-11-09 20:13:38 daily 0.8 https://www.321223.com/ 2026-11-09 20:13:18 daily 0.8 https://www.321223.com" 2026-11-09 20:12:58 daily 0.8 https://www.321223.com 2026-11-09 20:12:38 daily 0.8 http://www.321223.com<#if 2026-11-09 20:12:18 daily 0.8 http://www.321223.com/html/web/xinwenzhongxin/shipinzhuanqu/index.html 2026-11-09 20:11:58 daily 0.8 http://www.321223.com/html/web/xinwenzhongxin/fangdaxinwen/index.html 2026-11-09 20:11:38 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/zhaobiaogonggao/index.html 2026-11-09 20:11:18 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/zhaobiaogonggao/2103055327044489218.html 2026-11-09 20:10:58 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/zhaobiaogonggao/2102682494330130434.html 2026-11-09 20:10:38 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/zhongxingshangye/index.html 2026-11-09 20:10:18 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/yihangkeji/index.html 2026-11-09 20:09:58 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/xinshengfeixiang/index.html 2026-11-09 20:09:38 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/shouhangzhishengji/index.html 2026-11-09 20:09:18 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/index.html 2026-11-09 20:08:58 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/haihangkonggu/index.html 2026-11-09 20:08:38 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/fangdategang/index.html 2026-11-09 20:08:18 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/fangdatansu/index.html 2026-11-09 20:07:58 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/dongbeizhiyao/index.html 2026-11-09 20:07:38 daily 0.8 http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/chengdutancai/index.html 2026-11-09 20:07:18 daily 0.8 http://www.321223.com/html/web/shehuizeren/zhichiguofang/index.html 2026-11-09 20:06:58 daily 0.8 http://www.321223.com/html/web/shehuizeren/yifanashui/index.html 2026-11-09 20:06:38 daily 0.8 http://www.321223.com/html/web/shehuizeren/shehuigongyi/index.html 2026-11-09 20:06:18 daily 0.8 http://www.321223.com/html/web/shehuizeren/jienenghuanbao/index.html 2026-11-09 20:05:58 daily 0.8 http://www.321223.com/html/web/shehuizeren/baozhangjiuye/index.html 2026-11-09 20:05:38 daily 0.8 http://www.321223.com/html/web/rencaifazhan/zhaopingonggao/index.html 2026-11-09 20:05:18 daily 0.8 http://www.321223.com/html/web/guanyuwomen/zuzhijiagou/index.html 2026-11-09 20:04:58 daily 0.8 http://www.321223.com/html/web/guanyuwomen/fazhanlicheng/index.html 2026-11-09 20:04:38 daily 0.8 http://www.321223.com/html/web/guanyuwomen/fangdarongyu/index.html 2026-11-09 20:04:18 daily 0.8 http://www.321223.com/html/web/guanyuwomen/fangdajianjie/index.html 2026-11-09 20:03:58 daily 0.8 http://www.321223.com/html/web/dangjianwenhua/xingfufangda/index.html 2026-11-09 20:03:38 daily 0.8 http://www.321223.com/html/web/dangjianwenhua/qiyelinian/index.html 2026-11-09 20:03:18 daily 0.8 http://www.321223.com/html/web/dangjianwenhua/dangqunhuodong/index.html 2026-11-09 20:02:58 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/yiyao/index.html 2026-11-09 20:02:38 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/tansu/index.html 2026-11-09 20:02:18 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/tansu/ https:/www.cdcarbon.cn/intro/3.html 2026-11-09 20:01:58 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/tansu/ https:/www.cd-ts.cn/about/7.html 2026-11-09 20:01:38 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/tansu/ https:/fushuncarbon.com 2026-11-09 20:01:18 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/tansu/ http:/fdtsgs.com 2026-11-09 20:00:58 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/tansu/ /html/web/chengyuandanwei/tansu/1952972548200914946.html 2026-11-09 20:00:38 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/tansu/ /html/web/chengyuandanwei/tansu/1952971930770006018.html 2026-11-09 20:00:18 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/tansu/ /html/web/chengyuandanwei/tansu/1952969997875339266.html 2026-11-09 19:59:58 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/tansu/ /html/web/chengyuandanwei/tansu/1952966690133958658.html 2026-11-09 19:59:38 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/shangye/index.html 2026-11-09 19:59:18 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/hangkong/index.html 2026-11-09 19:58:58 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/index.html 2026-11-09 19:58:38 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ https:/www.jxfangda-steels.com/index/about/id/1.html 2026-11-09 19:58:18 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ https:/www.fddzsteel.com/dg_gywm/dg_qyjj/cindex1.html 2026-11-09 19:57:58 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ http:/www.scdesheng.com/ 2026-11-09 19:57:38 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ http:/www.nhi.com.cn/html/web/guanyuwomen/gongsijianjie/index.html 2026-11-09 19:57:18 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ http:/www.fangda-specialsteels.com/web/index.aspx 2026-11-09 19:56:58 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/2062069973823197186.html 2026-11-09 19:56:38 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/1952982209025204225.html 2026-11-09 19:56:18 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/1952981773291544577.html 2026-11-09 19:55:58 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/1952981140610146305.html 2026-11-09 19:55:38 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/1952980763097620482.html 2026-11-09 19:55:18 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/1952980411455561730.html 2026-11-09 19:54:58 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/1952980023696351234.html 2026-11-09 19:54:38 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/1952978003895705602.html 2026-11-09 19:54:18 daily 0.8 http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/1952977484364046338.html 2026-11-09 19:53:58 daily 0.8 http://www.321223.com/column/95/ 2026-11-09 19:53:38 daily 0.8 http://www.321223.com/column/94/ 2026-11-09 19:53:18 daily 0.8 http://www.321223.com/column/92/ 2026-11-09 19:52:58 daily 0.8 http://www.321223.com/column/138/ 2026-11-09 19:52:38 daily 0.8 http://www.321223.com/ 2026-11-09 19:52:18 daily 0.8 http://www.321223.com https://www.yzr.com.cn/micro/main/aboutus/63ca0a89b5240a7602621d60 2026-11-09 19:51:58 daily 0.8 http://www.321223.com https://www.ykfdyy.com/ 2026-11-09 19:51:38 daily 0.8 http://www.321223.com https://www.westair.cn/stcontent/menupage/f9515923-5f75-4801-a3f3-daf09cdbb133/fd170793-0f42-499e-b03a-bc0632fe0cc5/9f991f7f-89e1-4c22-b1c7-411156b46ef0 2026-11-09 19:51:18 daily 0.8 http://www.321223.com https://www.urumqi-air.com/micro/main/aboutus/641159f50c682c7801e5a149 2026-11-09 19:50:58 daily 0.8 http://www.321223.com https://www.tjys.com.cn/html/web/guanyuyihang/gongsijianjie/index.html 2026-11-09 19:50:38 daily 0.8 http://www.321223.com https://www.tianjin-air.com/stcontent/menupage/0bbd75f1-bc38-41c6-95f4-4e3644aa70b8/7c0ff667-57c6-4de5-8e7f-e9fa5b0d4ccb/766eab66-6b64-48f7-b6de-b2ab8c2e8742 2026-11-09 19:50:18 daily 0.8 http://www.321223.com https://www.nepharm.com.cn/html/web/liaojiewomen/gongsijianjie/index.html 2026-11-09 19:49:58 daily 0.8 http://www.321223.com https://www.luckyair.net/micro/main/aboutus/641d4bbf230c607e69a9a99f 2026-11-09 19:49:38 daily 0.8 http://www.321223.com https://www.jdair.net/micro/main/article/64599c7160a9be4d4434c960 2026-11-09 19:49:18 daily 0.8 http://www.321223.com https://www.hnasatc.edu.cn/xxgk/xxjj.htm 2026-11-09 19:48:58 daily 0.8 http://www.321223.com https://www.hnair.com/guanyuhaihang/hhgs/gsjj/ 2026-11-09 19:48:38 daily 0.8 http://www.321223.com https://www.hnacargo.com/Portal2/AboutUs.aspx 2026-11-09 19:48:18 daily 0.8 http://www.321223.com https://www.gxairlines.com/stdair/tcms?directoryName=foot&fileName=CompanyAndOverview 2026-11-09 19:47:58 daily 0.8 http://www.321223.com https://www.fuzhou-air.cn/micro/main/aboutus/63db6994257effa4641ba390 2026-11-09 19:47:38 daily 0.8 http://www.321223.com https://www.fd-yy.com/html/web/guanyuwomen/yiyuanjianjie/index.html 2026-11-09 19:47:18 daily 0.8 http://www.321223.com https://www.deerjet.com/about/advantage.html 2026-11-09 19:46:58 daily 0.8 http://www.321223.com https://www.airchangan.com/content/c2aafb9c-c9a1-414e-8182-000a082ff315 2026-11-09 19:46:38 daily 0.8 http://www.321223.com http://www.zxbusiness.com/web/gyzx?nid=1 2026-11-09 19:46:18 daily 0.8 http://www.321223.com http://www.hnatechnic.com/html/web/aboutus/gongsijianjie/index.html 2026-11-09 19:45:58 daily 0.8 http://www.321223.com http://www.3-hospital-cqmu.com 2026-11-09 19:45:38 daily 0.8 http://www.321223.com /html/web/chengyuandanwei/hangkong/1953010391426195457.html 2026-11-09 19:45:18 daily 0.8 http://www.321223.com /html/web/chengyuandanwei/hangkong/1953007446785712129.html 2026-11-09 19:44:58 daily 0.8 http://www.321223.com 2026-11-09 19:44:38 daily 0.8 https://jh53a.321223.com 2026-11-09 19:20:54 daily 0.8